Novel Biomarkers, Therapeutic Targets for Prevention and Treatment of Cardiovascular Diseases

by Iswarya on  December 27, 2018 at 2:51 PM Heart Disease News
RSS Email Print This Page Comment bookmark
Font : A-A+

New study finds that metabolomic biomarkers can help clinicians to identify cardiovascular disease risk and take preventive steps before the disease can surface. The findings of the study are published in the journal Cardiovascular & Hematological Disorders-Drug Targets.
Novel Biomarkers, Therapeutic Targets for Prevention and Treatment of Cardiovascular Diseases
Novel Biomarkers, Therapeutic Targets for Prevention and Treatment of Cardiovascular Diseases

Cardiovascular diseases (CVDs) are proven to be the leading cause of deaths throughout the world. If statistics are reviewed, almost four out of five deaths are due to myocardial infarction or stroke.

Efforts to prevent CVD have little effect on the decrease in the number of CVD related deaths despite many medical advances.

Therefore, the search for new and even better therapies and treatments for the betterment of those who are suffering from CVD is still in progress.

The field of metabolomics has offered a good solution to these diseases. Metabolomic biomarkers help clinicians to identify the risk of CVD and take preventive measures before the diseases can surface. Early diagnosis of CVD is a good sign for a patient's recovery and also for their health. Therefore, there is a need to establish reliable, sensitive and non-invasive biomarkers which can serve as therapeutic targets for the prevention and treatment of CVD.

In this study, analytical techniques are discussed along with the workflow that is used in untargeted metabolomics. Case studies that highlight the use of untargeted metabolomics in CVD research are also identified. Five of the case studies show approaches to identify untargeted metabolomics and apply this information in clinical situations. The analysis was conducted for the prediction of cardiovascular disease risk, myocardial ischemia, transient ischemic attack, incident coronary heart disease, and myocardial infarction risk.

The use of the untargeted metabolomics for risk assessment is still relatively new, and there is still a need for future advancements in metabolomics technologies.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

More News on:

Atherosclerosis 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive